Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Cellvera is working to develop antiviral solutions against SARS-CoV-2 and other viruses.
January 25, 2022
By: Kristin Brooks
Managing Editor, Contract Pharma
AiPharma, a global biopharmaceutical company developing innovative antiviral therapies, has completed a rebranding effort in response to company growth and to reflect its expanded business strategy. The company has relaunched under the brand name Cellvera. This transformation is the result of a redefined strategy that in addition to Cellvera’s exiting flagship, the antiviral portfolio expands its focus on diversified, innovative therapies and other treatment solutions for rare and difficult-to-treat illnesses. Cellvera aims to build a strong footprint in the space of virology, immunology, precision medication, and genetics, improving the lives of patients worldwide. Cellvera aspires to be at the forefront of pioneering integrated Artificial Intelligence discovery, manufacturing, and distribution platforms in bioscience. As part of Cellvera’s expanded strategic goals the company appointed Dr. Ashraf Allam as Executive Chairman. Dr. Allam has more than 30 years of experience in the life science industry across the globe. He served as the CEO of the Pharmaceutical Investment Company, which is wholly owned by the (KSA) Kingdom of Saudi Arabia Public Investment Fund (PIF), a global investment powerhouse and one of the most significant sovereign wealth funds in the world, with assets of more than $500 billion. Before that, Ashraf held several executive regional and global roles in large multinationals, in both listed and privately-owned companies, including Mundipharma, Amgen, Johnson & Johnson, Eli Lilly & Company, and Bristol Myers Squibb; he played a strategic role in setting up and managing their business. Alessandro Gadotti, CEO of Cellvera, said: “This is a very exciting time for the Cellvera team, and with Ashraf on board, I am confidently looking forward to achieving our goals and fulfilling the vision of building a robust global biopharma powerhouse ready to take the healthcare to another level. I strongly believe this is possible to achieve through the combination of science, AI, and digital diagnostics and technology, as well as through the unique partnerships with the top-tier allies pioneering the healthcare solutions of the new era.” Cellvera is working to develop effective antiviral solutions against SARS-CoV-2 and other viruses and will continue working with their existing and future partners to accomplish this.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !